Cargando…

Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients

The occurrence of cisplatin (CDDP)-induced nephrotoxicity (CIN) has decreased with advancements in supportive care. In contrast, we reported that baseline diabetes mellitus (DM) complications significantly worsen CIN. This study aimed to determine further risk factors associated with CIN development...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Yoshitaka, Kobayashi, Masaki, Tamaki, Shinya, Nakamura, Katsuyuki, Hirate, Daisuke, Takahashi, Kenta, Takekuma, Yoh, Sakakibara-Konishi, Jun, Shimizu, Yasushi, Kinoshita, Ichiro, Sugawara, Mitsuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564853/
https://www.ncbi.nlm.nih.gov/pubmed/37816823
http://dx.doi.org/10.1038/s41598-023-44477-w
_version_ 1785118568540536832
author Saito, Yoshitaka
Kobayashi, Masaki
Tamaki, Shinya
Nakamura, Katsuyuki
Hirate, Daisuke
Takahashi, Kenta
Takekuma, Yoh
Sakakibara-Konishi, Jun
Shimizu, Yasushi
Kinoshita, Ichiro
Sugawara, Mitsuru
author_facet Saito, Yoshitaka
Kobayashi, Masaki
Tamaki, Shinya
Nakamura, Katsuyuki
Hirate, Daisuke
Takahashi, Kenta
Takekuma, Yoh
Sakakibara-Konishi, Jun
Shimizu, Yasushi
Kinoshita, Ichiro
Sugawara, Mitsuru
author_sort Saito, Yoshitaka
collection PubMed
description The occurrence of cisplatin (CDDP)-induced nephrotoxicity (CIN) has decreased with advancements in supportive care. In contrast, we reported that baseline diabetes mellitus (DM) complications significantly worsen CIN. This study aimed to determine further risk factors associated with CIN development in DM patients. Patients with thoracic cancer requiring DM pharmacotherapy, who received CDDP (≥ 60 mg/m(2))-containing regimens using the short hydration method (n = 140), were enrolled in this retrospective multicenter observational study. The primary endpoint of the present study was the elucidation of risk factors (patient factors, DM medication influence, and treatment-related factors) associated with CIN development in patients with DM. Cisplatin-induced nephrotoxicity occurred in 22.1% of patients with DM. The median worst variation of serum creatinine levels and creatinine clearance (worst level − baseline level) was 0.16 mg/dL (range: − 0.12–1.41 mg/dL) and − 15.9 mL/min (− 85.5–24.3 mL/min), respectively. Multivariate logistic regression analyses identified female sex as the singular risk factor for CIN development in the DM population (adjusted odds ratio; 2.87, 95% confidence interval; 1.08–7.67, P = 0.04). Diabetes mellitus medication and treatment-related factors did not affect CIN development. In conclusion, our study revealed that female sex is significantly associated with CIN development in patients with DM and thoracic cancer.
format Online
Article
Text
id pubmed-10564853
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105648532023-10-12 Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients Saito, Yoshitaka Kobayashi, Masaki Tamaki, Shinya Nakamura, Katsuyuki Hirate, Daisuke Takahashi, Kenta Takekuma, Yoh Sakakibara-Konishi, Jun Shimizu, Yasushi Kinoshita, Ichiro Sugawara, Mitsuru Sci Rep Article The occurrence of cisplatin (CDDP)-induced nephrotoxicity (CIN) has decreased with advancements in supportive care. In contrast, we reported that baseline diabetes mellitus (DM) complications significantly worsen CIN. This study aimed to determine further risk factors associated with CIN development in DM patients. Patients with thoracic cancer requiring DM pharmacotherapy, who received CDDP (≥ 60 mg/m(2))-containing regimens using the short hydration method (n = 140), were enrolled in this retrospective multicenter observational study. The primary endpoint of the present study was the elucidation of risk factors (patient factors, DM medication influence, and treatment-related factors) associated with CIN development in patients with DM. Cisplatin-induced nephrotoxicity occurred in 22.1% of patients with DM. The median worst variation of serum creatinine levels and creatinine clearance (worst level − baseline level) was 0.16 mg/dL (range: − 0.12–1.41 mg/dL) and − 15.9 mL/min (− 85.5–24.3 mL/min), respectively. Multivariate logistic regression analyses identified female sex as the singular risk factor for CIN development in the DM population (adjusted odds ratio; 2.87, 95% confidence interval; 1.08–7.67, P = 0.04). Diabetes mellitus medication and treatment-related factors did not affect CIN development. In conclusion, our study revealed that female sex is significantly associated with CIN development in patients with DM and thoracic cancer. Nature Publishing Group UK 2023-10-10 /pmc/articles/PMC10564853/ /pubmed/37816823 http://dx.doi.org/10.1038/s41598-023-44477-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Saito, Yoshitaka
Kobayashi, Masaki
Tamaki, Shinya
Nakamura, Katsuyuki
Hirate, Daisuke
Takahashi, Kenta
Takekuma, Yoh
Sakakibara-Konishi, Jun
Shimizu, Yasushi
Kinoshita, Ichiro
Sugawara, Mitsuru
Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
title Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
title_full Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
title_fullStr Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
title_full_unstemmed Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
title_short Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
title_sort risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564853/
https://www.ncbi.nlm.nih.gov/pubmed/37816823
http://dx.doi.org/10.1038/s41598-023-44477-w
work_keys_str_mv AT saitoyoshitaka riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT kobayashimasaki riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT tamakishinya riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT nakamurakatsuyuki riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT hiratedaisuke riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT takahashikenta riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT takekumayoh riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT sakakibarakonishijun riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT shimizuyasushi riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT kinoshitaichiro riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients
AT sugawaramitsuru riskfactoranalysisforcisplatininducednephrotoxicitywiththeshorthydrationmethodindiabeticpatients